BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 9.03.2015

Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability

The Food and Drug Administration (FDA or the Agency) is announcing the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The recommendations provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled "Bioequivalence Recommendations for Specific Products," which explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site. The BE recommendations identified in this notice were developed using the process described in that guidance.

Source: Federal Register — Food and Drug AdministrationOpen original release →